Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PDI Effects on Tumor Microenvironment
Context: Although the development of immune checkpoint inhibitors has transformed treatment strategies of several human malignancies, research models to study immunotherapy in adrenocortical carcinoma (ACC) are lacking. Objective: To explore the effect of anti-PD1 immunotherapy on the alteration of...
Saved in:
Published in | The journal of clinical endocrinology and metabolism Vol. 105; no. 1; p. 26 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford University Press
01.01.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Context: Although the development of immune checkpoint inhibitors has transformed treatment strategies of several human malignancies, research models to study immunotherapy in adrenocortical carcinoma (ACC) are lacking. Objective: To explore the effect of anti-PD1 immunotherapy on the alteration of the immune milieu in ACC in a newly generated preclinical model and correlate with the response of the matched patient. Design, Setting, and Intervention: To characterize the CU-ACC2-M2B patient-derived xenograft in a humanized mouse model, evaluate the effect of a PD-1 inhibitor therapy, and compare it with the CU-ACC2 patient with metastatic disease. Results: Characterization of the CU-ACC2-humanized cord blood-BALB/c-[Rag2.sup.null][Il2n/.sup.null][Sirpa.sup.WOD] model confirmed ACC origin and match with the original human tumor. Treatment of the mice with pembrolizumab demonstrated significant tumor growth inhibition (60%) compared with controls, which correlated with increased tumor infiltrating lymphocyte activity, with an increase of human CD8+ T cells (P < 0.05), HLA-DR+ T cells (P < 0.05) as well as Granzyme [B.sup.+] [CD8.sup.+] T cells (<0.001). In parallel, treatment of the CU-ACC2 patient, who had progressive disease, demonstrated a partial response with 79% to 100% reduction in the size of target lesions, and no new sites of metastasis. Pretreatment analysis of the patient's metastatic liver lesion demonstrated abundant intratumoral [CD8.sup.+] T cells by immunohistochemistry. Conclusions: Our study reports the first humanized ACC patient-derived xenograft mouse model, which may be useful to define mechanisms and biomarkers of response and resistance to immune-based therapies, to ultimately provide more personalized care for patients with ACC. (J Clin Endocrinol Metab 105: 26-42, 2020) Keywords: Adrenocortical carcinoma, anti-PD-1, humanized mouse PDX model, immunotherapy |
---|---|
ISSN: | 0021-972X 1945-7197 |
DOI: | 10.1210/clinem/dgz014 |